Here is my study of VRX, checklist score 3.5/5
- 10/15/2019 – Citron longs on BHC (BHC-Turnaround) – I might need to return to BHC
- 04/25/2019 – Shares of Bausch Health, formerly Valeant, rise 3% on FDA approval of psoriasis treatment
Bausch Health, formerly known as Valeant Pharmaceuticals, said Thursday that it and its dermatology business, Ortho Dermatologics received approval from the Food and Drug Administration (FDA) for its DUOBRII lotion to treat plaque psoriasis.
- 12/13/2018 – Bausch Health Companies Acquires 2 Possible Blockbuster Drugs For $200 Million From Synergy Pharmaceuticals
- 11/19/2018 – Tracking John Paulson’s Paulson & Company Portfolio – Q3 2018 Update: about 10% of Paulson’s position is on BHC
- 11/13/2018 – CNBC’s Jim Cramer reveals how Bausch Health has put together an amazing comeback.
Shares of Bausch, which changed its name from Valeant in July 2018, have more than tripled from their April 2017 lows. The company’s latest quarterly report handily beat expectations on earnings and revenue, with organic revenue growth in all of its segments.
“How did Papa do it? First, he told us that he was going to start cleaning up the hideous balance sheet,” Cramer said. “Second, he explained that Valeant really did have an attractive pipeline of new drugs, they just needed to double down on developing the good ones. Third, he had to … motivate the staff. It was an incredibly dispirited workforce.”
The CEO’s hard work has already paid off, but according to Cramer, Bausch’s stock is “not done” and is “dirt-cheap” at its current price-to-earnings multiple of seven times next year’s earnings estimates.
“The bottom line? Joe Papa has orchestrated an amazing comeback at Bausch Health. The results speak for themselves, which is why I believe, in the end, this story has more room to run,” the “Mad Money” host said.
Piper Jaffary report on BHC litigation (Jaffray_on_BHC_litigation)
- 11/06/2018 – Bausch Health Companies Inc. 2018 Q3 – Results – Earnings Call Slides
- 11/06/2018 – Bausch Health tops revenue estimates in latest quarter
- Sept 17, 2018 – Joe Papa’s great interview on CNBC, Bausch Health CEO Joe Papa talks R&D, company’s turnaround, Jim Cramer sits down with Bausch Health Companies Chairman and CEO Joe Papa, who presents some of his pharmaceutical company’s new products and discusses the ongoing turnaround.
- Sept 12, 2018 – Two good news make stock price jumped by 14% today
Bausch Health Announces Resolution Of XIFAXAN® Intellectual Property Litigation
- May 08, 2018 news from Barron’s
Valeant Pharmaceuticals International (VRX) has climbed 11% to $20.18 after reporting better-than-expected earnings, raised its guidance and said it would change its name to Bausch Health Cos.
full content (study_of_VRX_Dec_2017)
